Louis Garguilo's Articles
-
RNAi vs. mRNA: Two Therapies, Two CDMO Strategies
7/1/2025
The biotech industry is often described in grand dichotomies such as innovator vs. generic, small vs. large molecule, or clinical vs. commercial. These differentiators influence development and manufacturing, CDMO selection and outsourcing strategies. There are also nuanced pairings, such as mRNA vs. RNAi.
-
Lonza Bets On Biologics. What's It Mean For You?
6/26/2025
It’s a large and universally recognizable CDMO, so this matters. Swiss-based powerhouse Lonza will increase its focus on biologics, and “advanced synthesis” including for antibody-drug conjugates (ADCs), cell and gene therapies (CGT), and mRNA therapeutics. Will other CDMOs follow suit? What's this say about the future of development outsourcing and our industry?
-
Late-Stage Formulation Is A Different Ballgame. Insights From An Allstar
6/19/2025
The art and science of late-stage/commercial formulation, compared to early-phase formulation, is a different ballgame, says Dileep Boinipally, currently utilizing CDMOs to advance a pipeline of oral and injectable candidates. He has a stadium full of advice for readers.
-
How A Biotech Navigates the CDMO Frenzy For GLP-1 Services
6/17/2025
Doug Bakan enjoys all the attention CDMOs give him nowadays at his biotech with GLP-1-related programs. But how is he selecting his external partners? Which are most trustworthy? Can he discern what they say is what they they're going to do? Here are his thoughts.
-
Early-Phase Formulation Done Right: An Expert Analysis
6/12/2025
Dileep Boinipally has extensive experience in formulation, manufacturing process development, and regulatory strategy. He’s adept at explaining all that, but Chief Editor Louis Garguilo got him to focus for readers on the ins-and-outs of the practice of early formulation development.
-
Billions Of Dollars In CDMO Secondary Packaging Of Biologics
6/10/2025
Chief Editor Louis Garguilo analyzes a report projecting the biologics CDMO secondary packaging market could rise from $2.59 billion this year to USD $5.50 billion by 2034. Projecting so far into the future is tricky business, but Garguilo explains the ultimate value.
-
A Psychedelic Path To CDMO Selection?
6/5/2025
"Be prepared. Structured. Work in a systematic fashion towards your CDMO selection." That's a rather non-psychedelic paraphrasing of Anthony Grenier, Reunion Neuroscience, a biotech pursuing the development of novel, synthetic psychedelic molecules. Here's more of his thoughts on CDMO selection.
-
Tariffs On Toys … And API? Biopharma As The Next Battleground
6/3/2025
Outsourcing drug development and manufacturing is an attempt at purposeful action in a web of interdependent contingencies. The contingency top-of-mind today is President Trump’s tariff strategy, and global "negotiations" that have ushered in a supply-chain disquietude.
-
Outsourcing GLP-1 Programs: Is There Capacity For Biotechs?
5/29/2025
CDMOs want GLP-1 projects. Doug Bakan of Kailera Therapeutics says, “We see companies growing their existing GLP-1 manufacturing capabilities or communicating plans to introduce them. Our job is to find out which in fact have capacity now, and the actual vision to continue to expand."
-
Evolve Or Fade Away? Biotech's Outsourcing Moment In Trump's Tariff Tangle
5/22/2025
Ali Pashazadeh is "a deep thinker" that our Chief Editor visits with annually. Recently, he asked Pashazadeh to help us think through the evolving policies of the new U.S. presidential administration and the tariff turbulence, as they relate to a biotech's development and manufacturing outsourcing.